Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 53, Issue 3, 2004, Pages 233-238

  Deporte Fety, R ^a   Simon, N ^b   Fumoleau, P ^a   Campone, M ^a   Kerbrat, P ^c   Bonneterre, J ^d   Fargeot, P ^e   Urien, S ^f  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b Université de Marseille   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e CENTRE GEORGES FRANÇOIS LECLERC   (France)

^f CENTRE RENÉ HUGUENIN   (France)

Author keywords

Anticancer drugs; Population pharmacokinetics; Vinorelbine

Indexed keywords

ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; NAVELBINE; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD; BLOOD LEVEL; BLOOD SAMPLING; BODY HEIGHT; BODY SURFACE; BODY WEIGHT; BREAST CARCINOMA; BREAST TUMOR; CLINICAL TRIAL; COMPARTMENT MODEL; CORRELATION COEFFICIENT; DRUG DETERMINATION; DRUG INFUSION; ENZYME METABOLISM; ENZYME MODIFICATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL ASSESSMENT; METABOLISM; METASTASIS; MULTICENTER STUDY; PATHOLOGY; PLASMA CLEARANCE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; VINBLASTINE;

EID: 1442286475     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0729-2     Document Type: Article

References (18)

1. Chatelut E, Boddy AV, Peng B, Rubie H, Lavit M, Dezeuze A, Pearson AD, Roche H, Robert A, Newell DR, Canal P (1996) Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 59:436
2. Freyer G, Tranchand B, Ligneau B, Ardiet C, Souquet PJ, Court-Fortune I, Riou R, Rebattu P, Boissel JP, Trillet-Lenoir V, Girard P (2000) Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 50:315
3. Gallo JM, Laub PB, Rowinsky EK, Grochow LB, Baker SD (2000) Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol 18:2459
4. Gauvin A, Pinguet F, Culine S, Astre C, Gomeni R, Bressolle F (2000) Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res 6:2690
5. Gauvin A, Pinguet F, Culine S, Astre C, Cupissol D, Bressolle F (2002) Blood and plasma pharmacokinetics of vinorelbine in elderly patients with advanced metastatic cancer. Cancer Chemother Pharmacol 49:48
6. Gauvin A, Pinguet F, Culine S, Astre C, Gomeni R, Bressolle F (2002) A limited-sampling strategy to estimate individual pharmacokinetic parameters of vinorelbine in elderly patients with advanced metastatic cancer. Anticancer Drugs 13:473
7. Gurney HP, Ackland S, Gebski V, Farrell G (1998) Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. J Clin Oncol 16:2299
8. Khayat D, Covelli A, Variol P (1995) Phase I and pharmacologic study of intravenous vinorelbine in patients with solid tumors. Proc Am Soc Clin Oncol 14:371
9. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F, Nicot G (1992) Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42:545
10. Mouly S, Aymard G, Tillement JP, Caulin C, Bergmann JF, Urien S (2001) Increased oral gancyclovir bioavailability in HIV-infected patients with chronic diarrhea and wasting syndrome - a population pharmacokinetic study. Br J Clin Pharmacol 51:557
11. Nguyen L, Tranchand B, Puozzo C, Variol P (2002) Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials. Br J Clin Pharmacol 53:459
12. Parke J, Charles BG (2000) Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model. Eur J Clin Pharmacol 56:481
13. Sabot C, Marquet P, Debord J, Carpentier N, Merle L, Lachatre G (1998) Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients. Eur J Clin Pharmacol 54:171
14. Schilling T, Fiebig HH, Kerpel-Fronius S, Winterhalter B, Variol P, Tresca P, Heinrich B, Hanauske AR (1996) Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patients. Invest New Drugs 14:371
15. Urien S (1997) MP2 (V 2.0) - a Windows application for population pharmacokinetics. In: Aarons L, Balant LP, Danhof M, et al (eds) The population approach: measuring and managing variability in response, concentration. European Community, Brussels, p 419
16. Urien S, Bree F, Breillout F, Bastian G, Krikorian A, Tillement JP (1993) Vinorelbine high-affinity binding to human platelets and lymphocytes: distribution in human blood. Cancer Chemother Pharmacol 32:231
17. Urien S, Fumoleau P, Campone M, Kerbrat P, Bonneterre J, Fargeot P, Deporte-Fety R (2003) Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer Chemother Pharmacol 52:99
18. Variol P, Nguyen L, Tranchand B, Puozzo C (2002) A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine. Eur J Clin Pharmacol 58:467